Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (January 2022)

28 slides from Day One Biopharmaceuticals's investor presentation, Jan 5, 2022

  1. Slide 1: Targeted Therapies for People of All Ages

    Slide 1: Targeted Therapies for People of All Ages

    Targeted Therapies for People of All Ages January 2022

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Day One: Cancer Drug Development for People of All Ages

    Slide 3: Day One: Cancer Drug Development for People of All Ages

    Day One: Cancer Drug Development for People of All Ages Mission That Creates Value Specialized Team DAY101 (tovorafenib) Lead Program Growing Portfolio and Runway Beyond Clinical Milestones Develop medicines for genomically-defined cancers Goal is to establish first-in-class position through rapid p

  4. Slide 4: Pediatric Markets Create Opportunity for High Impact and Capital Efficiency

    Slide 4: Pediatric Markets Create Opportunity for High Impact and Capital Efficiency

    Pediatric Markets Create Opportunity for High Impact and Capital Efficiency Lack of approved products create potential first-in-class opportunities Pricing flexibility for important new therapies Supportive and engaged advocacy and investigator community desiring better treatment options Early engag

  5. Slide 5: A Senior Team with Deep Experience Developing and Commercializing Products

    Slide 5: A Senior Team with Deep Experience Developing and Commercializing Products

    A Senior Team with Deep Experience Developing and Commercializing Products in Pediatric and Adult Oncology Markets Mike Preigh, PhD Chief Technical Officer Head of CMC at Array for 10+ years. Brought >20 drug candidates to IND & clinical development Lisa Bowers Chief Commercial Officer CEO of Rhia V

  6. Slide 6: Our Pipeline

    Slide 6: Our Pipeline

    Our Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones DAY101 (tovorafenib) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/DAY101) FDA Breakt

  7. Slide 7: DAY101 (tovorafenib) Type II Pan-RAF Inhibitor

    Slide 7: DAY101 (tovorafenib) Type II Pan-RAF Inhibitor

    DAY101 (tovorafenib) Type II Pan-RAF Inhibitor

  8. Slide 8: DAY101 Monotherapy Approach Focused on RAF Fusions; Combination Addresses MAPK Alterations

    Slide 8: DAY101 Monotherapy Approach Focused on RAF Fusions; Combination Addresses MAPK Alterations

    DAY101 (tovorafenib): Monotherapy Approach is Focused on RAF Fusions While Our Combination Strategy Addresses a Broad Set of MAPK Alterations DAY101 (tovorafenib) is a type II RAF inhibitor that selectively inhibits both monomeric and dimeric RAF kinase DAY101’s inhibition of both RAF monomers and d

  9. Slide 9: The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor

    Slide 9: The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor

    The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Because many pLGGs undergo senescence when patients reach their 20s, the goal of therapy is to maximize tumor control while minimizing treatment-associated toxicities from surgery, chemotherapy, and radia

  10. Slide 10: PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients

    Slide 10: PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients

    PNOC014 Study Results Demonstrated Responses or Stable Disease in Majority of pLGG Patients Treated with DAY101 (tovorafenib) Of the eight patients with RAF fusions (7 BRAF, 1 CRAF), two patients achieved a complete response by Response Assessment for Neuro-Oncology (RANO), three had a partial respo

  11. Slide 11: Results from Independent Radiology Review of PNOC014

    Slide 11: Results from Independent Radiology Review of PNOC014

    Results from Independent Radiology Review of PNOC014 RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO: Response assessment for neuro-oncology (FDA standard) Volumetric image analysis (exploratory) Best response from baseline Date of data cutoff: 02 JAN 2020 Wright K et. al.

  12. Slide 12: Multiple Rapid, Deep and Durable Responses Observed in PNOC014

    Slide 12: Multiple Rapid, Deep and Durable Responses Observed in PNOC014

    Multiple Rapid, Deep and Durable Responses Observed following Initiation of DAY101 (tovorafenib) Treatment of pLGG Patients in PNOC014 Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019

  13. Slide 13: Drug-related Adverse Events Observed for DAY101 in PNOC014

    Slide 13: Drug-related Adverse Events Observed for DAY101 in PNOC014

    Drug-related Adverse Events Observed for DAY101 (tovorafenib) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Toxicities Grade 1-2 Grade 3 Grade 4 Anemia 6 (67%) Hypophosphatemia 4 (44%) Fatigue 5 (55%) Rash 8 (89%) Achromotrichia 7 (78%) Pruritis 6 (67%) Photosensitivity 1 (11%)

  14. Slide 14: Pivotal Phase Study of Monotherapy DAY101 in pLGG (FIREFLY-1)

    Slide 14: Pivotal Phase Study of Monotherapy DAY101 in pLGG (FIREFLY-1)

    Pivotal Phase 2 Study of Monotherapy DAY101 (tovorafenib) in pLGG (FIREFLY-1) Abbreviations: LGG, low-grade glioma; ORR, objective response rate; C, cycle; D, day Study Design Screening Day –28 to 0 Enrollment/Baseline (C1D1) MRI: Baseline and every 3rd cycle Study Drug Administration 420mg/m2 QW El

  15. Slide 15: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    Slide 15: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    Incidence and Prevalence of BRAF-altered pLGG in the U.S. 2020 Estimated Incidence Under 25 US Population1 ~105,000,000 Rate of CNS Tumors (0.00521%)2 ~5,500 Gliomas (63%)2 ~3,500 Low Grade (77%)2 ~2,600 Has Received Drug Tx (58%)2 ~1,500 BRAF Mutated (70%)2 ~1,100 2017 Estimated SEER Prevalence Und

  16. Slide 16: Our Pipeline

    Slide 16: Our Pipeline

    Our Pipeline Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones DAY101 (tovorafenib) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/DAY101) FDA Breakt

  17. Slide 17: DAY101 is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors

    Slide 17: DAY101 is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors

    DAY101 (tovorafenib) is Active as a Monotherapy in Patients with RAF-altered Adult Solid Tumors and Has Shown Strong Synergy Preclinically in Combination Clinical activity demonstrated in relapsed melanoma patients; preclinical activity demonstrated in RAF fusions, BRAF non-V600 mutations, and BRAF

  18. Slide 18: Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers

    Slide 18: Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers

    Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers Associated with RAF Wild-type Fusions Botton T et al, Cell Reports, 2019 LY3009120: Lilly pan-RAFi Lifirafenib: Beigene pan-RAF/EGFRi CCT196969: CRUK RAF ”paradox breaker” Springworks 2020 Corp Presentation BRAFwt fu

  19. Slide 19: Phase Study of Monotherapy DAY101 in Solid Tumors (FIRELIGHT-1)

    Slide 19: Phase Study of Monotherapy DAY101 in Solid Tumors (FIRELIGHT-1)

    Phase 2 Study of Monotherapy DAY101 (tovorafenib) in Solid Tumors (FIRELIGHT-1) Trial Design1 Single arm, open-label, global phase 1b/2a study n = 40 patients (approximately) Eligibility: patients aged 12 years and older with non-hematologic tumor with an activating BRAF fusion, CRAF/RAF1 fusion, or

  20. Slide 20: Strong Scientific Rationale for Combining DAY101 with Additional MAPK Pathway Inhibitors

    Slide 20: Strong Scientific Rationale for Combining DAY101 with Additional MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining DAY101 (tovorafenib) with Additional MAPK Pathway Inhibitors Potential combinations Type II RAFi + MEKi Rationale BRAF fusion dimers are effectively inhibited by type II, but not type I RAFi MEK ERK RAF/MEK/ ERK PI3K/mTOR RAL Type II RAFi + Targeting multipl

  21. Slide 21: Pimasertib MEK1/2 Inhibitor

    Slide 21: Pimasertib MEK1/2 Inhibitor

    Pimasertib MEK1/2 Inhibitor

  22. Slide 22: Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors

    Slide 22: Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors

    Pimasertib: Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors Sources: Pimasertib Investigator Brochure, v12, 2019; de Gooijer et al., Int J Cancer, 2018; Shaw et al., AACR LB-456, 2012; Lebbe et al., Cancers, 2020. Pimasertib is an orally-bioavailable, selective, no

  23. Slide 23: Vertical MAPK Pathway Inhibition with DAY101 and Pimasertib

    Slide 23: Vertical MAPK Pathway Inhibition with DAY101 and Pimasertib

    Vertical MAPK Pathway Inhibition with DAY101 (tovorafenib) and Pimasertib Unlocks Potential Synergy for Adult Solid Tumors The MAPK pathway normally has multiple feedback loops that negatively regulate upstream (RAS/RAF) activation to ensure optimal signaling Monotherapy MEK inhibition disables thes

  24. Slide 24: DAY101/Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1)

    Slide 24: DAY101/Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1)

    DAY101 (tovorafenib) /Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncogene, serine/threonine kinase; MAPK, mitogen-activated protein kinase; NRAS, neuroblastoma rat sarcoma viral oncogene. 1Umbrella mas

  25. Slide 25: Summary

    Slide 25: Summary

    Summary

  26. Slide 26: Financial Summary: DAWN

    Slide 26: Financial Summary: DAWN

    Financial Summary: DAWN Cash and cash equivalents as of September 30, 2021: $297.2 million (no debt) IPO in May 2021: $184 million in gross proceeds, includes full exercise of underwriter’s option 61.9 million shares of common stock outstanding $ Millions Three Months Ended 9/30/21 Nine Months Ended

  27. Slide 27: Re-envisioning and Redefining Drug Development for People of All Ages

    Slide 27: Re-envisioning and Redefining Drug Development for People of All Ages

    Re-envisioning and Redefining Drug Development for People of All Ages – Starting at Day One DAY101 (tovorafenib) Oral, CNS-penetrant, pan-RAF PIMASERTIB Oral, allosteric MEK inhibitor SPECIALIZED TEAM pLGG: most common brain tumor in children, with no approved therapies Rapid and durable responses d

  28. Slide 28: Thank you

    Slide 28: Thank you

    NY Day One = BIOPHARMACEUTICALS Thank you

Source: SEC EDGAR · 8-K filed Jan 5, 2022

More decks from Day One Biopharmaceuticals Inc